Analysis of short-term efficacy and safety of pazopanib combined with chemotherapy in the treatment of advanced synovial sarcoma

Purpose To investigate the short-term efficacy and safety of pazopanib combined with chemotherapy in the treatment of advanced synovial sarcoma (SS). Methods A total of 64 patients with advanced synovial sarcoma treated with pazopanib combined with chemotherapy at our hospital from January 2018 to December 2023 were selected. Among them, 26 patients received first-line chemotherapy, 19 patients received second-line chemotherapy, and 19 patients received third-line chemotherapy. First-line chemotherapy regimens included anthracyclines and ifosfamide, while second-line and third-line chemotherapy drugs used included vincristine, docetaxel, gemcitabine, cisplatin, and dacarbazine. Therapeutic efficacy and safety were evaluated every 6 weeks. Results Out of the 64 patients, 33 achieved partial response (PR), 12 had stable disease (SD), and 19 experienced progression disease (PD). The objective response rate (ORR) and disease control rate (DCR) were 51.5%(33/64) and 70.3%(45/64), respectively, with a median progression-free survival (PFS) of 7.55 months (95%CI: 6.320~8.780 months). Among the 26 patients treated with the first-line regimen, ORR was 65.4%(17/26), DCR was 73.1%(19/26), and median PFS was 9.167 months (95% CI: 6.362~11.971 months). For the 19 patients receiving second-line therapy, ORR was 47.4%(9/19) DCR was 73.7%(14/19), and median PFS was 7.55 months (95% CI: 6.054~9.046 months). Among the 19 patients treated with the third-line regimen, ORR was 36.8%(7/19), DCR was 63.1%(12/19), and median PFS was 6.09 months (95% CI: 3.158~9.022 months). Common adverse events included fatigue, liver function impairment, hypertension, hair color changes, hematopoietic system